Veloci-Bi

Regeneron, CytomX Ink Potentially $2B Bispecific Immunotherapy Deal
BioSpace
Thu, 11/17/22 - 12:05 pm
Regeneron
CytomX Therapeutics
bispecifics
cancer
Veloci-Bi
drug development